Glioblastoma — Phase 2 trials
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Intra-arterial Cetuximab · Intra-arterial Mannitol — 1 site
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Pembrolizumab · Stereotactic Radiation Therapy · Surgical Resection — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
IA Carboplatin + Radiotherapy in Relapsing GBM
IA Carbo+ Radiation — 1 site
- TRIALPHASE2RECRUITING
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Simultaneous-integrated boost with IMRT — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
EBNK-001 + IL-15 + Pembrolizumab — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma
Survivin-targeted DC Cell Injection
- TRIALPHASE1 / PHASE2RECRUITING
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
LAM561 — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
pH Measurement of in vivo tissue — 1 site
- TRIALPHASE2RECRUITING
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Trastuzumab deruxtecan — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Near-Infrared Fluorescence Imaging · Panitumumab · Panitumumab-IRDye800 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
TGX-007 · Valaciclovir — 2 sites
- TRIALPHASE2RECRUITING
Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients
Temozolomide monotherapy · Chemo-Radiotherapy with concurrent temozolomide. — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
ADV/HSV-tk (gene therapy) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
LMP744 · Conventional Surgery or Biopsy — 1 site
- TRIALPHASE2RECRUITING
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Intra-arterial Cetuximab · Intra-arterial Mannitol · Hypofractionated re-irradiation — 1 site
- TRIALPHASE2RECRUITING
Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
ACT001 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
P134 cell injection — 1 site
- TRIALPHASE2RECRUITING
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Keto Diet · Standard Anti-Cancer Diet — 5 sites
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
ADI-PEG 20 (Arginine deiminase pegylated) · Temozolomide (TMZ) · Standard of Care Radiation Therapy (RT) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Rhenium Liposome Treatment — 3 sites
- TRIALPHASE2RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Cancer Therapeutic Procedure · Cancer Therapeutic Procedure · Questionnaire Administration — 1 site
- TRIALPHASE2RECRUITING
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Adaptive radiotherapy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debio 0123 · Temozolomide · Radiotherapy — 16 sites
- TRIALPHASE1 / PHASE2RECRUITING
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
D2C7-IT · 2141-V11 — 1 site
- TRIALPHASE2RECRUITING
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV · Temozolomide · Tetanus Diphtheria Vaccine — 13 sites
- TRIALPHASE1 / PHASE2RECRUITING
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
DB107-RRV · DB107-FC · Radiation Therapy (RT) — 5 sites
- TRIALPHASE2RECRUITING
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
IA Carboplatin + IA Caelyx · IA Carboplatin + IA Etoposide Phosphate — 1 site
- TRIALPHASE2 / PHASE3NOT_YET_RECRUITING
Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer
Intensity-Modulated Radiation Therapy · Hypofractionated Radiation Therapy · Temozolomide (TMZ)
- TRIALPHASE2RECRUITING
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
Intrathecal injection of thiotepa · Stupp regimen (oral temozolomide) · Radical radiotherapy — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.